Breaking News, Collaborations & Alliances

BioMed X Moves HQ to Heidelberg Innovation Park

Partnership with BioLabs expands lab access and life sciences collaboration.

Dr. Ann-Kristin Mueller, Site Director, BioLabs Heidelberg, and Dr. Thomas Rückle, Head of Research, BioMed X AG. Image: BioMed X / BioLabs Heidelberg.

BioMed X has announced plans to relocate its global headquarters to LAB22 at Heidelberg Innovation Park, and launched a global partnership with BioLabs, a provider of shared laboratory infrastructure for life science innovators.

Over the coming months, BioMed X will relocate its global headquarters to LAB22, Heidelberg Innovation Park’s newest landmark building for biotechnology, life sciences, and digital innovation. As part of this move, BioMed X’s Heidelberg-based scientific teams will transfer their laboratory operations to the research facilities of BioLabs Heidelberg, located in the same building.

Going forward, both organizations will explore opportunities to combine BioMed X’s expertise in scientific talent sourcing and innovative solution building with BioLabs’ laboratory infrastructure.

“This marks an exciting new chapter for BioMed X,” said Dr. Christian Tidona, Founder and CEO of BioMed X AG. “Our new headquarters at Heidelberg Innovation Park and our partnership with BioLabs give our researchers access to an outstanding scientific environment while allowing us to focus even more strongly on what we do best: identifying the biggest biomedical challenges, attracting exceptional talent, and building innovative solutions for our partners. At the same time, it brings our scientists closer to the startups, investors, and partners that make this ecosystem work, and gives us a strong foundation for our continued international growth.”

“We are excited to welcome BioMed X as our newest tenant at BioLabs Heidelberg. BioMed X constitutes a unique element of the Heidelberg innovation ecosystem, and their dynamic teams will be a fantastic addition to our startup community. We look forward to supporting BioMed X in their growth in Heidelberg and beyond,” said Dr. Johannes Fruehauf, President & CEO, BioLabs Founder & Chairman, LabCentral.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters